简介:AIM:Tofindouttheoutcomeoflaserphotocoagulationinclinicallysignificantmacularedema(CSME)byopticalcoherencetomography(OCT).·METHODS:Itwasaprospective,non-controlled,caseseriesstudyenrolling81eyesof64patientswithCSMEbetweenAugust2008andJanuary2010.AllpatientsreceivedmodifiedgridphotocoagulationwithfrequencydoubledNd:YAGlaser.Eachpatientwasevaluatedintermsofbest-correctedvisualacuity(BCVA)andregressionorprogressionofmaculopathyafterlasertherapyat1,3and6months.Spearman’scorrelationtestwasusedtoshowthecorrelationbetweenBCVAandtotalmacularvolume(TMV).Analysisofvariance(ANOVA)wasusedtocompareamonggroupsandindependentt-testwasusedtocompareineachgroup.·RESULTS:ThereishighcorrelationbetweenBCVAandTMV(P≤0.001).BCVAimprovedin50.6%,remainedstaticin39.5%anddeterioratedin9.9%patientsafter6monthoftreatment.TheBaselineTMV(meanandSD)were9.26±1.83,10.4±2.38,11.5±3.05,8.89±0.75and9.47±1.98mm3fordifferentOCTpatterns,ST(spongelikethickening),CMO(cystoidmacularedema),SFD(subfovealdetachment),VMIA(Vitreomacularinterfaceabnormality)andaverageTMVrespectively(P=0.04).After6monthsoflasertreatment,themeanTMVdecreasedfrom9.47±1.98mm3to8.77±1.31mm3(P=0.01).InSTtherewassignificantdecreaseinTMV,P=0.01,Furtherwithinthesegroupsat6months,theyweresignificantlydifferent,P=0.01.·CONCLUSION:OCTshowedthedifferentmorphologicalvariantofCSMEwhiletheresponseoftreatmentisdifferent.TMVdecreasedthemostandhenceshowedtheimprovementinvisionafter6monthsoflasertreatment.IntheeraofAntivascularendothelialgrowthfactors(VEGFs),efficacyoflaserseemstobeinshadowbutitisstillfirstlineoftreatmentindevelopingnationlikeNepalwhereantiVEGFsmaynotbeeasilyavailableandaffordable.
简介:AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra
简介:目的:观察糖尿病视网膜病变(diabeticretinopathy,DR)患者行全视网膜光凝(panretinalphotocoagulation,PRP)后服药前及服药2mo后患眼的全视野视网膜电图(fullfieldelectroretinogram,ERG)变化,探讨递法明片对DR暗适应功能的保护作用。方法:选择在我医院就诊的重度非增殖性糖尿病视网膜病变(nonproliferativediabeticretinopathy,NPDR)患者55例55眼,随机分为治疗组和对照组。两组均行全视网膜光凝,治疗组光凝后口服递法明片,对照组口服维生素B1片2次/d,10mg/次。PRP后服药前及服药2mo后行全视野视网膜电图检查,观察其暗视视杆反应的变化并进行统计学处理。结果:两组患者服药前及服药2mo后,暗视视杆反应bT值组内及组间比较差异均无统计学意义(P〉0.05);治疗组bA值服药2mo后与服药前相比振幅升高,差异有统计学意义(P〈0.05),与对照组相比治疗组振幅升高较大,差异有统计学意义(P〈0.05)。结论:递法明片可减轻PRP治疗对视网膜的损害,改善患者的暗适应功能。
简介:AIM:ToinvestigatethesideeffectsofthecommonlyusedlasertreatmentalongwithtestingtheneuroprotectiveeffectofbFGFonapotentialretinalimpairment.METHODS:Todothis,30chinchillapigmentedadultmalerabbitsweredividedintothecontrolandexperimentalgroups.ThecontrolandexperimentalgroupsunderwentbothlaserapplicationandbFGFtreatment.Theretinaltissueimpairmentanditsrenewalrateweretestedunderthelightandelectronmicroscopicallevels.RESULTS:Thefocallaserapplicationonrabbiteyescausedmorphologicalalterationsbothintheapplicationregionandintheneighbouringareas.Inthedamagedareas,theouternuclearlayeroftheneuralretinawasalmostdisappeared,retinapigmentepitheliumwasinterrupted,theretinapigmentepitheliummigratedintraretinally,andthedamagedregionalongwithneighbouringareasseemedtobenotseparated.bFGFapplicationjustafterthelaserphotocoagulation,revealedbetterresultsinapplicationareas.CONCLUSION:ItcouldbesuggestedthatthebFGFapplicationfollowinglaserphotocoagulationmighthaveprotective,repairingandwoundhealingeffectsontheretina.
简介:青光眼是全球第二大致盲性眼病,全球有近4亿青光眼患者,我国青光眼的患病率约为1.3%,居世界第二位,约有2300万青光眼患者。临床上青光眼导致的失明占整个眼科致盲的25%-40%,是世界上第一位不可逆性致盲性眼病。目前为止,人类尚无一种有效治疗手段能够治愈这一疾病。患者一旦出现视力下降、视物模糊、眼红眼痛等症状就需要及时就医,青光眼对视力的损害是不可逆转的,最终可能导致失明。青光眼的病理基础是眼压升高,眼压的调节功能会受到影响,视物模糊会使患者以为自己只是看花眼了。患者往往通过眼部不适症状判断自己是否患有青光眼,这是一种非常主观的判断方法。那么青光眼有哪些症状呢?
简介:贝代单抗(bevacizumab)是近几年出现的重组单克隆抗体,通过抑制血管内皮生长因子(VEGF)达到抑制新生血管生成的作用。在眼科中,对于角膜、虹膜、脉络膜、视网膜的新生血管及年龄相关性黄斑变性、黄斑水肿等疾病的治疗具有很可观的应用前景。
简介:目的通过安徽省某县09年度与11年度分别开展的贫困白内障复明手术各300例(300眼),手术结果的比较,探讨防盲手术培训的重要性。方法手术均由通过培训与再培训并获得资格认证的两位医生完成。术前视力〈0.1,排除其他眼病及严重全身疾病。手术方式统一为小切口非超声乳化白内障摘除及人工晶状体植入术,植入的人工晶状体均为Alton晶状体,粘弹剂为玻璃酸钠(其胜,上海产)。术前、术后处理按照安徽省防盲手术要求执行。结果比较两年度病人的早期术后视力,术中及术后早期并发症,09年度与11年度比较,术后第一天裸眼视力≥0.3比率由49.5%上升至60.4%;术中玻璃体脱出由7%降至4%;角膜水肿发生率由16%降至11%;其他并发症同样明显减少。而每例白内障手术时间也由40分钟减少至22分钟。结论11年度手术质量明显好于09年。并且09年手术是在省防盲中心派一名教师现场指导下完成,而11年度则是完全是独立完成。这些结果均提示通过有效的防盲手术培训,能以明显的提高白内障手术质量;同时也充分证实了防盲手术培训是非常重要的。
简介:目的:探索一种临床实用的前房深度相对定量测量法,初步确定老年人前房深度的正常参考值。方法:裂隙灯光源外转45°,受检眼直视裂隙光,在6点时钟方向测量六个点的前房深度(ABCDEF),以角膜缘处的角膜厚度(CT值)为1计。A:角巩膜缘黑白交界处;B:A点上移1CT;C:B点上移1CT;D:虹膜最高点;E:瞳孔缘;F:晶状体前极。测量了50~75岁的正常老年人,229例229眼,采用双盲法对22例44眼进行了11次重复性检测。结果:女性组ABCDEF点的前房深度均值分别为0.38,0.58,0.89,2.10,2.65和3.26CT;男性组分别为0.71,1.02,1.43,2.37,2.90,3.41CT。女性组每个点的深度均比男性浅(P〈0.05),越近周边部越显著。结论:前房深度六点相对定量测量法可重复性好,实用性强。
简介:目的:探讨Avastin与Lucentis对人脐静脉血管内皮细胞(humanumbilicalveinendothelialcells,HUVEC)增殖和迁移的影响,了解其抑制血管生成的途径。方法:采用MTT比色法研究相同浓度Avastin与Lucentis对HUVEC增殖作用的差异;Transwell小室检测相同浓度Avastin与Lucentis对HUVEC迁移作用的差异。结果:MTT比色法显示,各浓度Avastin组、Lucentis组与对照组相比,吸光度值具有统计学差异(P〈0.05),相同浓度Avastin组与Lucentis组吸光度值无统计学差异(P〉0.05);Transwell分析方法显示,各浓度Avastin组、Lucentis组与对照组相比,HUVEC迁移率具有统计学差异(P〈0.05),相同浓度Avastin组与Lucentis组HUVEC细胞迁移率无统计学差异(P〉0.05)。结论:Avastin与Lueentis均可以抑制HUVEC增殖和迁移:随着药物浓度增加,对HUVEC增殖和迁移的抑制作用增强;相同浓度Avastin与Lucentis在体外实验中对HUVEC增殖和迁移的抑制作用无统计学差异(P〉0.05)。
简介:目的:研究柚皮素对激光诱发大鼠脉络膜新生血管形成(CNV)、高眼压兔眼血流和缺血大鼠眼视网膜功能恢复的作用。方法:选择雄性棕色挪威大鼠,采用激光诱发Bruch膜破裂后,予10g/L(20mg/kg)柚皮素,1次/d,持续4wk;光凝后2,4wk分别做眼底荧光血管造影,评估CNV的形成。采用彩色微球技术、眼电生理技术检测兔眼血流和大鼠视网膜功能恢复。结果:与对照组比较,10g/L柚皮素能明显增加高眼压兔眼脉络膜血流(P〈0.05),能明显增加缺血大鼠眼视网膜功能恢复(P〈0.05),能明显减轻光凝点荧光素渗漏(75.8%~95.0%,P〈0.01)。结论:柚皮素能抑制激光诱发大鼠络膜新生血管形成;增加高眼压兔眼脉络膜血流;增加缺血大鼠眼视网膜功能恢复。